Can you hear us now? The impact of health-care utilization by rare disease patients in the United States
- PMID: 34183788
- PMCID: PMC8553605
- DOI: 10.1038/s41436-021-01241-7
Can you hear us now? The impact of health-care utilization by rare disease patients in the United States
Abstract
Purpose: The vast majority of rare diseases (RDs) are complex, disabling, and life-threatening conditions with a genetic origin. RD patients face significant health challenges and limited treatments, yet the extent of their impact within health care is not well known. One direct method to gauge the disease burden of RDs is their overall cost and utilization within health-care systems.
Methods: The 2016 Healthcare Cost and Utilization Project (HCUP) databases were used to extract health-care utilization data using International Classification of Diseases, Tenth Revision (ICD-10) codes.
Results: Of 35.6 million national hospital weighted discharges in the HCUP Nationwide Inpatient Sample, 32% corresponded to RD-associated ICD-10 codes. Total charges were nearly equal between RDs ($768 billion) compared to common conditions (CCs) ($880 billion) (p < 0.0001). These charges were a result of higher charges per discharge and longer length of stay (LOS) for RD patients compared to those with CCs (p < 0.0001). Health-care cost and utilization was similarly higher for RDs with pediatric inpatient stays, readmissions, and emergency visits.
Conclusion: Pediatric and adult discharges with RDs show substantially higher health-care utilization compared to discharges with CCs diagnoses, accounting for nearly half of the US national bill.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures

Similar articles
-
Pediatric acquired demyelinating syndrome (ADS) in inpatient hospital settings: The hospitalization rate, costs, and outcomes in the US.Mult Scler Relat Disord. 2019 Sep;34:150-157. doi: 10.1016/j.msard.2019.06.031. Epub 2019 Jun 27. Mult Scler Relat Disord. 2019. PMID: 31295724
-
Inpatient health care utilization in the United States among children, adolescents, and young adults with nephrotic syndrome.Am J Kidney Dis. 2013 Jun;61(6):910-7. doi: 10.1053/j.ajkd.2012.12.025. Epub 2013 Feb 20. Am J Kidney Dis. 2013. PMID: 23434062
-
Estimating the burden and economic impact of pediatric genetic disease.Genet Med. 2019 Aug;21(8):1781-1789. doi: 10.1038/s41436-018-0398-5. Epub 2018 Dec 20. Genet Med. 2019. PMID: 30568310 Free PMC article.
-
The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence.Pharmacoeconomics. 2019 Feb;37(2):155-167. doi: 10.1007/s40273-018-0726-2. Pharmacoeconomics. 2019. PMID: 30315512 Free PMC article. Review.
-
Comorbidities Associated With Adult Inpatient Stays, 2019.2022 Dec 15. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb–. Statistical Brief #303. 2022 Dec 15. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb–. Statistical Brief #303. PMID: 36622929 Free Books & Documents. Review.
Cited by
-
Measuring the impact of rare diseases in Tasmania, Australia.Orphanet J Rare Dis. 2024 Oct 28;19(1):399. doi: 10.1186/s13023-024-03343-2. Orphanet J Rare Dis. 2024. PMID: 39468681 Free PMC article.
-
Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.Orphanet J Rare Dis. 2022 May 7;17(1):186. doi: 10.1186/s13023-022-02342-5. Orphanet J Rare Dis. 2022. PMID: 35526036 Free PMC article. Review.
-
Rare diseases, common barriers: disparities in pediatric clinical genetics outcomes.Pediatr Res. 2023 Jan;93(1):110-117. doi: 10.1038/s41390-022-02240-3. Epub 2022 Aug 13. Pediatr Res. 2023. PMID: 35963884 Free PMC article.
-
The health-care utilization and economic burden in patients with genetic skeletal disorders.Orphanet J Rare Dis. 2024 Mar 4;19(1):99. doi: 10.1186/s13023-024-03102-3. Orphanet J Rare Dis. 2024. PMID: 38438867 Free PMC article.
-
Socio-economic costs of rare diseases and the risk of financial hardship: a cross-sectional study.Lancet Reg Health West Pac. 2023 Feb 23;34:100711. doi: 10.1016/j.lanwpc.2023.100711. eCollection 2023 May. Lancet Reg Health West Pac. 2023. PMID: 37283971 Free PMC article.
References
-
- Shah RR. Regulatory framework for the treatment of orphan diseases. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford. 2006.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous